Rob Johnson
Advertisement
Articles by Rob Johnson
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Merck and Kelun’s Sac-TMT Extends Survival by Nearly 7 Months in Pretreated Endometrial Cancer
2
BMS Reports Death in Phase 1 Zolacabtagene Autoleucel MS Study
3
The BioPharm Brief: Survival Gains, a Modest ADC Win, and CAR-T in Multiple Sclerosis
4
BioNTech’s HER2 ADC Hits Phase 3 Goal, but Companies See Limited Benefit
5